Hepatitis C virus infection in African Americans

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 82-91

  Pearlman, Brian L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Hepatitis C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AFRICAN AMERICAN; ALOPECIA; ANEMIA; CANCER MORTALITY; CAUCASIAN; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; GENOTYPE; HEPATITIS C; HUMAN; INJECTION SITE REACTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNITED STATES; VOMITING; XEROSIS;

AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS;

EID: 29244481171     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498512     Document Type: Review

References (61)

1. Kim WR. The burden of hepatitis C in the US. Hepatology 2002; 36(5 Suppl 1):S30-4.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(3 Suppl 1):62S-5S.
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States. N Engl J Med 1999; 341:556-62.
4. Bonds DE, Zaccaro DJ, Karter AJ, Selby JV, Saad M, Goff DC. Ethnic and racial differences in diabetes care. Diabetes Care 2003; 26:1040-6.
5. American Heart Association. 2003 Heart disease and stroke statistics-update. Dallas: American Heart Association, 2002.
6. Advani AS, Atkeson B, Brown CL, et al. Barriers to the participation of African American patients with cancer in clinical trials. Cancer 2003;97:1499-506.
7. African American. In: Encylopedia encarta, MSN. Available at: http: //encarta.msn.com/encylopedia_761587467 /African_Americans.html. Accessed 26 July 2005.
8. Witzig R. The medicalization of race: scientific legitimatization of a flawed social construct. Ann Intern Med 1996; 125:675-9.
9. Hobbs F, Stoops N. Demographic trends in the 20th century. US Census Bureau, census 2000. Special reports series CENSR-4. Washington, DC: US Government, 2002. Available at http://www.census.gov/prod/ 2002pubs/censr-4.pdf. Accessed 26 April 2005.
10. Kelen GD, Green GB, Purcell RH, et al. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med 1992; 326:1399-404.
11. Seeff LB, Miller RN, Rabkin CS, et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105-11.
12. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97:700-6.
13. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30:787-93.
14. Lau JY, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996; 124:868-76.
15. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000; 119:1317-23.
16. Alter MJ, Margolis HS. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47(RR-19):1-39.
17. Alter MJ, Gallagher M, Morris TT, et al. Acute non-a-e hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997; 336:741-6.
18. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119:1385-96.
19. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908-14.
20. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C infection. JAMA 2000; 284:450-6.
21. Bhonacini M, Groshen S, Yu MC, Govindarajan S, Lindsay KL. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles county. Am J Gastroenterol 2001; 96:2438-41.
22. Mallat DB, Jeffers L. The natural history of HCV infection in African Americans. Am J Gastroenterol 2002; 97:520-1.
23. Crosse K, Umeadi OG, Anania FA, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2:463-8.
24. Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2:469-73.
25. Jacobson I, Brown R, McCone J, et al. Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African Americans compared to flat dose ribavirin with peginterferon alfa-2b combination therapy. Hepatology 2004; 40(4 Suppl 1):217A.
26. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706-14.
27. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933-41.
28. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512.
29. Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37:590-9.
30. Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 16-21.
31. Oleksyk TK, Thio CL, Truelove AL, et al. Single nucleotide polymorphisms and haplotypes in the IL 10 region associated with HCV clearance. Genes Immun 2005; 6:347-57.
32. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
33. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:S27-34.
34. Nguyen MH, Whittemore AS, Garcia RT, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004; 2:820-4.
35. De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African Americans with chronic hepatitis C. Hepatogastroenterology 2002; 49: 788-92.
36. Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001; 8: 264-9.
37. Theodore D, Shiffman ML, Sterling RK, et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003; 48:140-5.
38. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004; 6:66-70.
39. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117:163-8.
40. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-72.
41. Linday KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403.
42. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
43. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
44. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and nonhispanic whites. N Engl J Med 2004; 350:2265-71.
45. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91:1374-9.
46. Jeffers L, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-8.
47. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-13.
48. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226-31.
49. Neuman, AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
50. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African Americans and white patients treated with interferon and ribavirin. Hepatology 2003; 37:1343-50.
51. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001; 65:510-6.
52. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 2003; 37:795-801.
53. Ikura Y, Morimoto H, Hohmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996; 91:1367-73.
54. Barton AI, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995; 103:419-24.
55. Van Theil DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20:410-5.
56. Reed WW, Diehl LF. Leukopenia, neutropenia and reduced hemoglobin levels in healthy American Blacks. Arch Intern Med 1991; 151:501-5.
57. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36:1273-9.
58. Howell CD, Jeffers LS, Hu S, Lopez-Talavera JC. Safety and adherence to peginterferon alfa-2a plus ribavirin in black Americans with chronic hepatitis C genotype 1 [abstract 106885]. Gastroenterology 2004; 126(4 Suppl 2):M1236.
59. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
60. Toriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
61. Chung RY, Andersen J, Volberding P, Robbins GK, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.